The Scoop
Italian biotech firm NanoPhoria, developing inhalable therapies for heart disease, secured €83.5M to advance NP-MP1 to human trials. The therapy delivers biologics directly to target tissues.
The Context
NanoPhoria’s novel approach targets cardiovascular diseases with precision drug delivery. The non-viral nanoparticle platform promises enhanced treatment with fewer side effects. This investment reflects growing interest in innovative drug delivery systems and their potential to improve therapeutic outcomes in cardiology, one of the leading causes of death globally.